Search - tctmd.com

Displaying 741 - 760 of 883

Sort: Relevancy | Date

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

Presentation TCT 2016

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Pharmacotherapy for Hybrid PCI/CABG Cases

Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

Presentation TCT 2016

ACS Case Presentation: Where Pharmacotherapy Failed

Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Presenter: C. Michael Gibson, Daniel I. Simon, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Presenter: C. Michael Gibson, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation

2016 TCTMD Exercise Survey

October 26, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation ESC 2016

ESC-EAS Guidelines for the Management of Dyslipidaemias

Presenter: Ian Graham

August 27, 2016

Presentation ESC 2016

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Presenter: Patrizio Lancellotti

August 27, 2016

Presentation

Outcomes Among Older Stable Angina Patients Prescribed Beta-Blockers After PCI

Presenter: AA. Motivala

August 17, 2016

Presentation

Ambient Air Pollution Is Associated With the Severity of Coronary Atherosclerosis and Incident MI in Patients Undergoing Elective Cardiac Evaluation

Presenter: J. Hartiala

August 03, 2016

Advertisement

Heart Failure Advances (Ivabradine, ARNI, and More)

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Pharmacotherapy for Hybrid PCI/CABG Cases

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

ACS Case Presentation: Where Pharmacotherapy Failed

Limitations of Pharmacotherapy Clinical Trial Design

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

2016 TCTMD Exercise Survey

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

ESC-EAS Guidelines for the Management of Dyslipidaemias

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Outcomes Among Older Stable Angina Patients Prescribed Beta-Blockers After PCI

Ambient Air Pollution Is Associated With the Severity of Coronary Atherosclerosis and Incident MI in Patients Undergoing Elective Cardiac Evaluation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content